newsfilter
← Latest News
GlobeNewswire·

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ALPHA3 Enrollment Momentum Continues, Supported by Expanding Trial Network, Increased MRD Screening, and Brisk Enrollment in Asia-PacificNext ALPHA3